Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View

• Main Authors: Abdelrahim, M. (Author), Abdel-Wahab, N. (Author), Abudayyeh, A. (Author), Chang, J.C (Author), Diab, A. (Author), Esmail, A. (Author), Gaber, A.O (Author), Ghobrial, R.M (Author), Kaseb, A.O (Author), Murakami, N. (Author), Saharia, A. (Author)
• Format: Article
• Language: English
• Published: MDPI 2022
• Subjects: allograft rejection; CTLA-4 inhibitors; hepatocellular carcinoma; immune checkpoint inhibitors; immunotherapy; liver transplantation; PD-1 inhibitors; transplant oncology
• Online Access: View Fulltext in Publisher
• ISBN: 20726694 (ISSN)
• DOI: 10.3390/cancers14071760

Hepatocellular carcinoma (HCC) represents the second most common cause of cancer-related deaths and accounts for over eighty percent of primary liver cancers worldwide. Surgical resection and radiofrequency ablation in small tumors are included in the treatment options for HCC patients with good liver function profiles. According to the Milan Criteria, only a small portion of HCC patients are eligible for liver transplantation due to advanced-stage disease and large tumor size preventing/delaying organ allocation. Recently, the use of anti-programmed cell death protein 1 and programmed cell death ligand 1 (PD-1 and PD-L1) checkpoint inhibitors in the treatment of cancers have evolved rapidly and these therapies have been approved for the treatment of HCC. Immune checkpoint inhibitors have resulted in good clinical outcomes in pre-and post-transplant HCC patients, although, some reports showed that certain recipients may face rejection and graft loss. In this review, we aim to illustrate and summarize the utilization of immune checkpoint inhibitor therapies in pre-and post-liver transplants for HCC patients and discuss the assessment of immune checkpoint inhibitor regulators that might determine liver transplant outcomes. © 2022 by the authors. Licensee MDPI, Basel, Switzerland.